Population Pharmacokinetics of Polymyxin B-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Polymyxin B

Published:2018-01-08 Issue:3 Volume:104 Page:534-538
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Manchandani Pooja¹,Thamlikitkul Visanu²,Dubrovskaya Yanina³,Babic Jessica T.⁴,Lye David C.⁵⁶,Lee Lawrence S.⁶,Tam Vincent H.¹⁷

Affiliation:

1. Department of Pharmacological and Pharmaceutical Sciences; University of Houston College of Pharmacy; Houston Texas USA

2. Faculty of Medicine Siriraj Hospital; Mahidol University; Bangkok Thailand

3. Department of Pharmacy; New York University Langone Medical Center; New York New York USA

4. Department of Pharmacy; Baylor St. Luke's Medical Center; Houston Texas USA

5. Institute of Infectious Diseases and Epidemiology; Tan Tock Seng Hospital; Singapore

6. Department of Medicine, Yong Loo Lin School of Medicine; National University of Singapore; Singapore

7. Department of Pharmacy Practice and Translational Research; Houston Texas USA

Funder

Health Systems Research and Development Project (Faculty of Medicine Siriraj Hospital, Thailand)

Thai Health Promotion Foundation

Health Systems Research Institute (Thailand)

Government Pharmaceutical Organization (Thailand)

Singapore Ministry of Health Communicable Diseases Public Health Research Grant

Singapore National Medical Research Council Clinician Scientist Award grant

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.981/fullpdf

Reference23 articles.

1. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches;Karaiskos;Expert Opin. Pharmacother.,2014

2. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options;Vergidis;Curr. Opin. Investig. Drugs,2008

3. Drugs of last resort? The use of polymyxins and tigecycline at US Veterans Affairs medical centers, 2005-2010;Huttner;PLoS One,2012

4. Polymyxin antibiotics for gram-negative infections;Arnold;Am. J. Health Syst. Pharm.,2007

5. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series;Pastewski;Ann. Pharmacother.,2008

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A simple HPLC–MS/MS method for the determination of polymyxin B in human plasma and its application in the pharmacokinetic study in elderly patients infected with multidrug-resistant Gram-negative bacteria;Frontiers in Pharmacology;2024-08-16

2. Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation;Xenobiotica;2024-07-08

3. How can polymyxin B be dosed based on current pharmacokinetic knowledge?;European Journal of Clinical Pharmacology;2024-06-07

4. A pharmacovigilance study of adverse events associated with polymyxins based on the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database;Expert Opinion on Drug Safety;2024-05

5. A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction;Journal of Pharmacokinetics and Pharmacodynamics;2024-04-16